177 related articles for article (PubMed ID: 11346217)
1. Pharmacology of moxonidine: an I1-imidazoline receptor agonist.
Ernsberger P
J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S27-41. PubMed ID: 11346217
[TBL] [Abstract][Full Text] [Related]
2. A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.
Ernsberger P; Haxhiu MA; Graff LM; Collins LA; Dreshaj I; Grove DL; Graves ME; Schäfer SG; Christen MO
Cardiovasc Drugs Ther; 1994 Mar; 8 Suppl 1():27-41. PubMed ID: 8068578
[TBL] [Abstract][Full Text] [Related]
3. Why imidazoline receptor modulator in the treatment of hypertension?
Schäfer SG; Kaan EC; Christen MO; Löw-Kröger A; Mest HJ; Molderings GJ
Ann N Y Acad Sci; 1995 Jul; 763():659-72. PubMed ID: 7677385
[TBL] [Abstract][Full Text] [Related]
4. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
Ernsberger P; Friedman JE; Koletsky RJ
J Hypertens Suppl; 1997 Jan; 15(1):S9-23. PubMed ID: 9050981
[TBL] [Abstract][Full Text] [Related]
5. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites.
Ernsberger P; Damon TH; Graff LM; Schäfer SG; Christen MO
J Pharmacol Exp Ther; 1993 Jan; 264(1):172-82. PubMed ID: 8380858
[TBL] [Abstract][Full Text] [Related]
6. Effects of the selective I1 imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats.
Glavin GB; Smyth DD
Br J Pharmacol; 1995 Feb; 114(4):751-4. PubMed ID: 7773534
[TBL] [Abstract][Full Text] [Related]
7. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla.
Haxhiu MA; Dreshaj I; Schäfer SG; Ernsberger P
J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S1-8. PubMed ID: 7533221
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
Ziegler D; Haxhiu MA; Kaan EC; Papp JG; Ernsberger P
J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S26-37. PubMed ID: 8872297
[TBL] [Abstract][Full Text] [Related]
9. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
Ollivier JP; Christen MO
J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
[TBL] [Abstract][Full Text] [Related]
10. Site-dependent inhibition of neuronal c-jun in the brainstem elicited by imidazoline I1 receptor activation: role in rilmenidine-evoked hypotension.
Wang X; Li G; Abdel-Rahman AA
Eur J Pharmacol; 2005 May; 514(2-3):191-9. PubMed ID: 15910806
[TBL] [Abstract][Full Text] [Related]
11. Moxonidine: a new antiadrenergic antihypertensive agent.
Prichard BN; Graham BR; Owens CW
J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
[TBL] [Abstract][Full Text] [Related]
12. Selective stimulation of I1-imidazoline receptors as a novel mechanism for antihypertensive action. Focus on moxonidine.
Papp JG; Ollivier JP
J Cardiovasc Pharmacol; 1994; 24 Suppl 1():v-vi. PubMed ID: 7533220
[No Abstract] [Full Text] [Related]
13. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Prichard BN; Owens CW; Graham BR
J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
[TBL] [Abstract][Full Text] [Related]
14. Receptors involved in moxonidine-stimulated atrial natriuretic peptide release from isolated normotensive rat hearts.
Mukaddam-Daher S; Menaouar A; Gutkowska J
Eur J Pharmacol; 2006 Jul; 541(1-2):73-9. PubMed ID: 16774751
[TBL] [Abstract][Full Text] [Related]
15. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
Prichard BN; Graham BR
Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
[TBL] [Abstract][Full Text] [Related]
16. [New trends in the treatment of arterial hypertension: identification of the I1 receptor and the pharmacology of imidazoline].
Pavlović P
Vojnosanit Pregl; 1998; 55(3):305-10. PubMed ID: 9720446
[No Abstract] [Full Text] [Related]
17. Prototypical imidazoline-1 receptor ligand moxonidine activates alpha2-adrenoceptors in bulbospinal neurons of the RVL.
Hayar A; Guyenet PG
J Neurophysiol; 2000 Feb; 83(2):766-76. PubMed ID: 10669492
[TBL] [Abstract][Full Text] [Related]
18. alpha(2)-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice.
Tolentino-Silva FP; Haxhiu MA; Waldbaum S; Dreshaj IA; Ernsberger P
Brain Res; 2000 Apr; 862(1-2):26-35. PubMed ID: 10799665
[TBL] [Abstract][Full Text] [Related]
19. Role of I(1)-imidazoline receptors and alpha2-adrenoceptors in hemodynamic effects of moxonidine administration into the rostroventrolateral medulla.
Khokhlova ON; Murashev AN; Medvedev OS
Bull Exp Biol Med; 2001 Apr; 131(4):336-9. PubMed ID: 11550020
[TBL] [Abstract][Full Text] [Related]
20. Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?
van Zwieten PA
Am J Cardiovasc Drugs; 2001; 1(5):321-6. PubMed ID: 14728014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
